Upon Acquiring the Remaining 25% Stake in Bayer Zydus Pharma Pvt Ltd, Bayer completes its ownership

As per the reports, Bayer has recently acquired the remaining 25 percent stakes in Bayer Zydus Pharma Private Ltd for ₹282 crore. This acquisition marks the conclusion of a 13-year joint venture with Zydus Lifesciences Ltd. Bayer’s investment is aligned with pre-determined terms, encouraging it to attain full ownership of the entity.

The joint venture Bayer Zydus Pharma was established on the 28th of January in 2011. This 50:50 joint venture was dedicated to selling and marketing pharmaceutical products in India. Bayer purchased 25 percent of the stakes in 2018, and the partnership extended for three years.  

The joint venture's success is attributable to Bayer's expertise in commercializing novel products, advanced administration and sales processes adhering to international standards, Zydus Cadila’s robust Indian marketing and sales mastery and its exceptional logistical network within the industry. Reinforced by solid research and development initiatives and an innovative therapeutic approach, Bayer Zydus Pharma remains committed to fulfilling the healthcare needs of patients in India.

Post-acquisition of Bayer Zydus Pharma,  Shweta Rai, Managing Director - India and country division head - South Asia, Bayer Pharmaceuticals Division, asserted to maintain the commitment of the company to a robust presence in India as it assumes full ownership of Bayer Zydus Pharma Private Ltd.